% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • gatorgal50 gatorgal50 Mar 13, 2013 10:23 AM Flag


    Trius Therapeutics (NASDAQ:TSRX): JMP Securities recommends purchasing Trius shares ahead of the company’s second Phase 3 study for tedizolid in complicated skin infections. The firm has noted that the results will likely be reported during the month, and it predicts that the results will be positive. JMP Securities keeps its Outperform rating and a $12 price target on the stock. Also, Piper Jaffray recommends purchasing Trius Therapeutics shares prior to the ESTABLISH-2 study data later in the month. The firm predicts that positive data will drive Trius shares higher, and it believes that the company is a potential acquisition candidate. Piper reiterates its Overweight rating and an $11 price target on the stock.

    Sentiment: Strong Buy